Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds–synthesis, biological activity, and structural evaluation
作者:Piotr Stępnicki、Olga Wronikowska-Denysiuk、Agata Zięba、Katarzyna M. Targowska-Duda、Agata Bartyzel、Martyna Z. Wróbel、Tomasz M. Wróbel、Klaudia Szałaj、Andrzej Chodkowski、Karolina Mirecka、Barbara Budzyńska、Emilia Fornal、Jadwiga Turło、Marián Castro、Agnieszka A. Kaczor
DOI:10.1080/14756366.2023.2209828
日期:2023.12.31
multi-target ligand of G-protein-coupled receptors (GPCRs), in particular D2, 5-HT1A, and 5-HT2A receptors. Such receptor profile may be beneficial for the treatment of schizophrenia. Compounds 1–16 were designed, synthesised, and subjected to further evaluation. Their affinities for the above-mentioned receptors were assessed in radioligand binding assays and efficacy towards them in functional assays. Compounds
摘要 精神分裂症是一种慢性精神障碍,现有的抗精神病药物治疗效果不佳。本研究重点是通过优化化合物 D2AAK3 来寻找新的抗精神病药物,D2AAK3 是 G 蛋白偶联受体 (GPCR) 的多靶点配体,特别是 D 2 、5-HT 1A 和5 - HT 2A受体。这种受体谱可能有益于精神分裂症的治疗。化合物1 – 16被设计、合成并进行进一步评估。在放射性配体结合测定中评估它们对上述受体的亲和力,并在功能测定中评估它们对它们的功效。化合物1和10根据受体谱选择的药物进行了体内测试,以评估其抗精神病活性以及对记忆和焦虑过程的影响。进行分子建模以研究所研究的化合物与D 2、5-HT 1A和5-HT 2A受体在分子水平上的相互作用。最后,对化合物1进行了X射线研究,揭示了其在固态下的稳定构象。